Candesartan cilexetil – a review of effects on cardiovascular complications in hypertension and chronic heart failure

By Meredith Peter A.  

Current Medical Research and Opinion, Vol. 23, Iss. 7, 2007-07 ,pp. : 1693-1705

Informa Healthcare

Access to resources Recommend Favorite

Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy

By Devereux Richard B.   de Faire Ulf   Fyhrquist Frej   Harris Katherine E.   Ibsen Hans   Kjeldsen Sverre E.   Lederballe-Pedersen Ole   Lindholm Lars H.   Nieminen Markku S.   Omvik Per   Oparil Suzanne   Wedel Hans   Hille Darcy A.   Dahlöf Björn  

Current Medical Research and Opinion, Vol. 23, Iss. 2, 2007-02 ,pp. : 259-270

Informa Healthcare

Access to resources Recommend Favorite

Blood pressure reduction with olmesartan in mild-to-moderate essential hypertension: a planned interim analysis of an open label sub-study in German patients

By Böhm Michael   Ewald Silke    

Current Medical Research and Opinion, Vol. 22, Iss. 7, 2006-07 ,pp. : 1375-1380

Informa Healthcare

Access to resources Recommend Favorite

Evaluating Safety of Long-Acting Beta Agonists (LABAs) in Patients with Asthma

By  

Current Drug Safety, Vol. 5, Iss. 3, 2010-07 ,pp. : 245-250

Bentham Science Publishers

Access to resources Recommend Favorite

Hemodynamic and Hormonal Effects of the Angiotensin II Antagonist, Candesartan Cilexetil, in Patients with Congestive Heart Failure

By  

Cardiology, Vol. 93, Iss. 3, 2000-08 ,pp. : 175-182

Karger

Access to resources Recommend Favorite